Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.20 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: sotrastaurin, midostaurin, ucn-01 +2 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 4 pathways; mostly iron and oxidative stress | 0.80 |
Knock down and overexpress PRKCI in a dopamine neuron, astrocyte and microglia tri-culture; measure reactive oxygen species (CellROX) and lipid peroxidation and labile iron and dopamine neuron survival after α-synuclein fibril challenge.
- Cell type
- a dopamine neuron, astrocyte and microglia tri-culture
- Direction
- Both arms: public data does not say which way helps; existing compounds already reach the inhibition arm.
- Molecular readout
- reactive oxygen species (CellROX) and lipid peroxidation and labile iron
- Functional readout
- dopamine neuron survival after α-synuclein fibril challenge
- Rule-out
- If neither arm moves reactive oxygen species (CellROX) by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of PRKCI in a tri-culture of iPSC dopamine neurons, astrocytes and microglia; n = 3 differentiations; readouts: reactive oxygen species (CellROX) and lipid peroxidation and labile iron; dopamine neuron survival after α-synuclein fibril challenge. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- PRKCI in dopamine neurons, braak+0.48 (p 0.192) → +0.12 (p 0.759)receipt 2027
Swarm cases
receipt 2027: PRKCI in dopamine neurons, braak
- power
- full sample +0.21 (p 0.403, n 18), 95% CI -0.28 to +0.62. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.19 (p 0.460, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.31 (p 0.218, n 18). could be the mix.
- skeptic
- leave-one-out range +0.09 to +0.32, sign flips 0; without severely affected donors +0.21 (p 0.403, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for PRKCI in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts